This article summarizes five key news items for pharma marketers on February 6, 2026. It covers Novo Nordisk’s legal action against Hims & Hers for selling compounded Wegovy, skepticism around the TrumpRx initiative for discounted drugs, a roadblock encountered by Vertex Pharmaceuticals’ CRISPR sickle cell treatment, a widespread shortage of menopause treatment, and the Department of Health and Human Services’ development of an AI tool for vaccine monitoring.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Five things for pharma marketers to know for Friday, February 6, 2026
This article summarizes five key news items for pharma marketers on February 6, 2026. It covers Novo Nordisk’s legal action against Hims & Hers for selling compounded Wegovy, skepticism around the TrumpRx initiative for discounted drugs, a roadblock encountered by Vertex Pharmaceuticals’ CRISPR sickle cell treatment, a widespread shortage of menopause treatment, and the Department of Health and Human Services’ development of an AI tool for vaccine monitoring.